Vascular Endothelial Growth Factor Receptor-2
"Vascular Endothelial Growth Factor Receptor-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.
| Descriptor ID |
D040301
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.200 D12.776.543.750.630.750.200 D12.776.543.750.750.400.910.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor Receptor-2- Vascular Endothelial Growth Factor Receptor-2
- Vascular Endothelial Growth Factor Receptor 2
- KDR Tyrosine Kinase
- Tyrosine Kinase, KDR
- VEGFR-2
- Fetal Liver Kinase-1
- Fetal Liver Kinase 1
- Kinase Insert Domain Receptor
- VEGF Receptor Flk-1
- Flk-1, VEGF Receptor
- VEGF Receptor Flk 1
- VEGF Receptor KDR
- KDR, VEGF Receptor
- Flk-1 Protein
- Flk 1 Protein
- Flk-1 Receptor Tyrosine Kinase
- Flk 1 Receptor Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-2".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-2".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 5 | 6 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 6 | 7 |
| 2011 | 1 | 2 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 3 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 3 | 3 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in Profiles.
-
Injectable aptamer-functionalized nucleic acid-collagen hydrogels as a bioactive platform for angiogenic applications. Biomater Adv. 2026 Mar; 180:214580.
-
Molecular analysis of knockdown resistance (kdr) mutations in the voltage-gated sodium channel gene of Aedes aegypti populations from Saudi Arabia. Parasit Vectors. 2022 Oct 19; 15(1):375.
-
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res. 2022 06 01; 28(11):2229-2236.
-
Angiosarcoma of the Pancreas in a Pediatric Patient With an Activating KDR-Internal Tandem Duplication: A Case Report and Review of the Literature. J Pediatr Hematol Oncol. 2022 Apr 01; 44(3):e751-e755.
-
Anti-VEGF-R2 Aptamer and RGD Peptide Synergize in a Bifunctional Hydrogel for Enhanced Angiogenic Potential. Macromol Biosci. 2021 02; 21(2):e2000337.
-
c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis. Cells. 2019 05 23; 8(5).
-
TFEB controls vascular development by regulating the proliferation of endothelial cells. EMBO J. 2019 02 01; 38(3).
-
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
-
Generation of Cardiomyocytes From Vascular Adventitia-Resident Stem Cells. Circ Res. 2018 08 31; 123(6):686-699.
-
Intravitreal Stanniocalcin-1 Enhances New Blood Vessel Growth in a Rat Model of Laser-Induced Choroidal Neovascularization. Invest Ophthalmol Vis Sci. 2018 02 01; 59(2):1125-1133.